These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14707453)

  • 1. Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia.
    Kövesi G; Szende B
    Oncology; 2003; 65(4):331-6. PubMed ID: 14707453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progression of leukoplakia is associated with changes in apoptotic and mitotic index as well as in p53 and Ki-67 expression].
    Kövesi G; Szende B
    Magy Onkol; 2002; 46(4):333-8. PubMed ID: 12563356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias.
    Nasser W; Flechtenmacher C; Holzinger D; Hofele C; Bosch FX
    J Oral Pathol Med; 2011 Sep; 40(8):629-35. PubMed ID: 21435003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of cyclin D1, p27, and p63 in oral leukoplakia.
    Kövesi G; Szende B
    J Oral Pathol Med; 2006 May; 35(5):274-7. PubMed ID: 16630290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia.
    Gissi DB; Gabusi A; Tarsitano A; Luccarini L; Morandi L; Montebugnoli L
    J Craniomaxillofac Surg; 2018 May; 46(5):759-764. PubMed ID: 29588189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia.
    Kurokawa H; Matsumoto S; Murata T; Yamashita Y; Tomoyose T; Zhang M; Fukuyama H; Takahashi T
    J Oral Pathol Med; 2003 Oct; 32(9):513-21. PubMed ID: 12969225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathological and immunohistochemical study of malignant transformation of oral leukoplakia, with special reference to apoptosis-related gene products and proliferative activity.
    Nogami T; Kuyama K; Yamamoto H
    Acta Otolaryngol; 2003 Aug; 123(6):767-75. PubMed ID: 12953781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of cyclin D1, p27 and p63 expression in oral leukoplakia].
    Kövesi G; Szende B
    Magy Onkol; 2004; 48(4):309-13. PubMed ID: 15655576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of the p53 tumor-suppressor gene product in oral leukoplakia.
    Wood MW; Medina JE; Thompson GC; Houck JR; Min KW
    Otolaryngol Head Neck Surg; 1994 Dec; 111(6):758-63. PubMed ID: 7527509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 immunoprofiling of potentially malignant oral disorders: a case series analysis.
    Reddy VM; Kamath A; Radhakrishnan RA
    Indian J Cancer; 2012; 49(1):27-32. PubMed ID: 22842165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative cell-cycle protein expression in oral cancer assessed by computer-assisted system.
    Soares CP; Zuanon JA; Teresa DB; Fregonezi PA; Neto CB; Oliveira MR; Donadi EA; Martinelli-Kläy CP; Soares EG
    Histol Histopathol; 2006 Jul; 21(7):721-8. PubMed ID: 16598671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53, epidermal growth factor receptor, c-erbB2 in oral leukoplakias and oral squamous cell carcinomas.
    Singla S; Singla G; Zaheer S; Rawat DS; Mandal AK
    J Cancer Res Ther; 2018; 14(2):388-393. PubMed ID: 29516925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between p62 expression and clinicopathological characteristics in oral leukoplakia.
    Yoshida T; Terabe T; Nagai H; Uchida F; Hasegawa S; Nagao T; Miyabe S; Ishibashi-Kanno N; Yamagata K; Warabi E; Gosho M; Yanagawa T; Bukawa H
    Clin Exp Dent Res; 2019 Aug; 5(4):389-397. PubMed ID: 31452949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunohistochemical analysis of the p53 tumor suppressor gene product in oral leukoplakia].
    Kikegawa A
    Kokubyo Gakkai Zasshi; 2001 Mar; 68(1):51-9. PubMed ID: 11321806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of p53 and bcl-2 oncoprotein expression in precancerous lesions of the oral cavity.
    Sulkowska M; Famulski W; Chyczewski L; Sulkowski S
    Neoplasma; 2001; 48(2):94-8. PubMed ID: 11478700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p53, p63, podoplanin and Ki-67 in recurring versus non-recurring oral leukoplakia.
    Sundberg J; Pandey S; Giglio D; Holmberg E; Kjeller G; Kovács A; Sand LP; Tokozlu B; Öhman J; Sapkota D; Hasséus B
    Sci Rep; 2021 Oct; 11(1):20781. PubMed ID: 34675318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative verrucous leukoplakia of the gingiva.
    Fettig A; Pogrel MA; Silverman S; Bramanti TE; Da Costa M; Regezi JA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Dec; 90(6):723-30. PubMed ID: 11113818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia.
    Nagao T; Warnakulasuriya S; Sakuma H; Miyabe S; Hasegawa S; Machida J; Suzuki K; Fukano H; Shimozato K; Hashimoto S
    J Oral Pathol Med; 2017 May; 46(5):346-352. PubMed ID: 27605086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midkine expression in oral squamous cell carcinoma and leukoplakia.
    Jham BC; Costa NL; Silva JM; de Miranda AC; Oliveira JC; Silva TA; Batista AC
    J Oral Pathol Med; 2012 Jan; 41(1):21-6. PubMed ID: 21595751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.